This company has been marked as potentially delisted and may not be actively trading. GlycoMimetics (GLYC) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for GLYC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for GlycoMimetics and its competitors. Enter your email to sign up for newsletter Sign Up GLYC Analyst Ratings Over TimeTypeCurrent Forecast8/12/24 to 8/12/251 Month Ago7/13/24 to 7/13/253 Months Ago5/14/24 to 5/14/251 Year Ago8/13/23 to 8/12/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)0 Buy rating(s)Hold0 Hold rating(s)1 Hold rating(s)2 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price TargetN/AN/AN/A$1,000.00Forecasted UpsideN/AN/AN/A5,585.05% UpsideConsensus RatingBuyModerate BuyHoldHold GLYC Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History GLYC Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table GlycoMimetics Stock vs. The CompetitionTypeGlycoMimeticsMedical CompaniesS&P 500Consensus Rating Score 3.00 2.81 2.53Consensus RatingBuyModerate BuyModerate BuyPredicted UpsideN/A12,636.69% Upside12.92% UpsideNews Sentiment RatingNeutral NewsSee Recent GLYC NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/21/2025Cantor Fitzgerald4 of 5 starsEric SchmidtSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight7/26/2024TD Cowen4 of 5 starsT. BancroftSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/4/2024HC Wainwright1 of 5 starsE. WhiteSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral5/6/2024Capital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingN. QuibriaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal WeightAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:44 PM ET. GLYC Forecast - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares. Does GlycoMimetics's stock price have much downside? According to analysts, GlycoMimetics's stock has a predicted downside of NaN based on their 12-month stock forecasts. Do Wall Street analysts like GlycoMimetics more than its competitors? Analysts like GlycoMimetics more than other "medical" companies. The consensus rating for GlycoMimetics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GLYC compares to other companies. Stock Forecasts and Research Tools Related Companies LVTX Stock Forecast SLGL Stock Forecast ALXO Stock Forecast OVID Stock Forecast MRSN Stock Forecast RANI Stock Forecast XLO Stock Forecast KPTI Stock Forecast CLSD Stock Forecast SNYR Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:GLYC) was last updated on 8/12/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access